Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial

BACKGROUND: The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor anta...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruscitti, Piero, Masedu, Francesco, Alvaro, Saverio, Airò, Paolo, Battafarano, Norma, Cantarini, Luca, Cantatore, Francesco Paolo, Carlino, Giorgio, D'Abrosca, Virginia, Frassi, Micol, Frediani, Bruno, Iacono, Daniela, Liakouli, Vasiliki, Maggio, Roberta, Mulè, Rita, Pantano, Ilenia, Prevete, Immacolata, Sinigaglia, Luigi, Valenti, Marco, Viapiana, Ombretta, Cipriani, Paola, Giacomelli, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742232/
https://www.ncbi.nlm.nih.gov/pubmed/31513665
http://dx.doi.org/10.1371/journal.pmed.1002901

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742232/
https://www.ncbi.nlm.nih.gov/pubmed/31513665
http://dx.doi.org/10.1371/journal.pmed.1002901

Ejemplares similares